 REDWOOD CITY, Calif., Feb. 17, 2021 GLOBE NEWSWIRE -- Coherus BioSciences, Inc. Nasdaq: CHRS, the Company, Coherus announced that the United States Food and Drug Administration FDA has accepted for review the 351k Biologics License Application BLA for CHS-1420, a Humira adalimumab biosimilar product candidate, and has set a Biosimilar User Fee Act action date for December 2021. If approved, Coherus plans to launch the adalimumab biosimilar in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie. 